MediWound (NASDAQ:MDWD – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports.

Avantax Advisory Services Inc. boosted its position in Vericel Co. (NASDAQ:VCEL – Free Report) by 1.7% during the 4th quarter ...

Q4 2024 Results Conference Call March 19, 2025 8:30 AM ETCompany ParticipantsDan Ferry - IR, LifeSci AdvisorsOfer Gonen - ...

A probable case was defined by an IgM-positive ELISA or the presence of an eschar if blood testing could not be performed. A confirmed case was defined by a positive qPCR test, an IgM-positive ...

Reported positive results from the Expanded Access Protocol (NEXT), reinforcing NexoBrid's clinical and real-world benefits across 29 burn centers in the U.S. The study included 239 patients (215 ...

A webcast of the presentations will be available on the Investor Relations section of the Vericel Corporation website at: https://investors.vcel.com.

YAVNE, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its ...

MediWound’s first drug, NexoBrid ®, is an FDA- and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, significantly reducing the need ...

Examination revealed edema of the left ear lobe. On the posterior surface there was a small ulcerated papule, covered by a dry black eschar and surrounded by an area of erythema. No adenopathy was ...

So as I mentioned, we have two products. The first one on the left is NexoBrid. NexoBrid is a drug for eschar removal for severe burns. In order to remove SCAR in burns, this was horrible image on the ...